Hypoxia signaling: Challenges and opportunities for cancer therapy

被引：31

作者：

Ivan, Mircea ^{[1
,2
]}

Fishel, Melissa L. ^{[3
,4
]}

Tudoran, Oana M. ^{[5
]}

Pollok, Karen E. ^{[3
]}

Wu, Xue ^{[6
]}

Smith, Paul J. ^{[7
]}

机构：

[1] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA

[2] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA

[3] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA

[4] IU Simon Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN USA

[5] Oncol Inst Prof Dr Ion Chiricuta, Cluj Napoca, Cluj, Romania

[6] Ohio State Univ, Columbus, OH USA

[7] Cardiff Univ, Sch Med, Cardiff, Wales

来源：

SEMINARS IN CANCER BIOLOGY | 2022年 / 85卷

关键词：

Hypoxia; HIF1; HIF2; HIF inhibitors; Hypoxia-activated prodrug; SMALL-MOLECULE INHIBITOR; ANTI-ANGIOGENIC THERAPY; DNA TOPOISOMERASE-II; CYTOCHROMES P450 CYP; RENAL-CELL CARCINOMA; INDUCIBLE FACTOR; ACTIVATED PRODRUG; N-OXIDE; HEPATOCELLULAR-CARCINOMA; PROLYL HYDROXYLASE;

D O I：

10.1016/j.semcancer.2021.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.

引用

页码：185 / 195

页数：11

共 50 条

[1] Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities
Shant Qinxiang Sin
Chakrabhavi Dhananjaya Mohan
Robby Miguel Wen-Jing Goh
Mingliang You
Siddaiah Chandra Nayak
Lu Chen
Gautam Sethi
Kanchugarakoppal Subbegowda Rangappa
Lingzhi Wang
Cancer and Metastasis Reviews, 2023, 42 : 741 - 764
[2] Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities
Sin, Shant Qinxiang
Mohan, Chakrabhavi Dhananjaya
Goh, Robby Miguel Wen-Jing
You, Mingliang
Nayak, Siddaiah Chandra
Chen, Lu
Sethi, Gautam
Rangappa, Kanchugarakoppal Subbegowda
Wang, Lingzhi
CANCER AND METASTASIS REVIEWS, 2023, 42 (03) : 741 - 764
[3] Notch signaling, hypoxia, and cancer
Guo, Mingzhou
Niu, Yang
Xie, Min
Liu, Xiansheng
Li, Xiaochen
FRONTIERS IN ONCOLOGY, 2023, 13
[4] Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, Xiufang
Zhang, Miaofeng
Xu, Faying
Jiang, Shaojie
MOLECULAR CANCER, 2020, 19 (01)
[5] Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Yuqing
Coleman, Morgan
Brekken, Rolf A.
CANCERS, 2021, 13 (12)
[6] PET imaging of cardiac hypoxia: Opportunities and challenges
Handley, M. G.
Medina, R. A.
Nagel, E.
Blower, P. J.
Southworth, R.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 51 (05) : 640 - 650
[7] Hypoxia as a target for drug combination therapy of liver cancer
Bowyer, Cressida
Lewis, Andrew L.
Lloyd, Andrew W.
Phillips, Gary J.
Macfarlane, Wendy M.
ANTI-CANCER DRUGS, 2017, 28 (07) : 771 - 780
[8] VHL and Hypoxia Signaling: Beyond HIF in Cancer
Zhang, Jing
Zhang, Qing
BIOMEDICINES, 2018, 6 (01)
[9] Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy
Anastasiadis, AG
Bemis, DL
Stisser, BC
Salomon, L
Ghafar, MA
Buttyan, R
CURRENT DRUG TARGETS, 2003, 4 (03) : 191 - 196
[10] Hypoxia Signaling in Cancer: From Basics to Clinical Practice
Sebestyen, Anna
Kopper, Laszlo
Danko, Titanilla
Timar, Jozsef
PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27

← 1 2 3 4 5 →